Warp Sciences Launches With $215 Million for AI Labs
The South San Francisco startup aims to build U.S.-based chemistry research services using automation and AI.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Should the U.S. prioritize keeping pharmaceutical and biotech research discovery processes within domestic borders?
South San Francisco-based Warp Sciences has emerged from stealth with $215 million in funding to build a U.S.-based chemistry contract research organization. The company uses automated labs and AI to speed up drug discovery.
Why it matters
The company aims to shorten the path from molecular design to testing while keeping research operations within the United States. This strategy aligns with the industry trend to localize research services following the passage of the BIOSECURE Act.
Warp Sciences uses automated laboratory systems to run experiments and AI models trained on that physical data to iterate on molecular designs. The company's initial service focuses specifically on lead optimization analog synthesis.
The players
Warp Sciences
A South San Francisco-based chemistry contract research organization that utilizes AI and robotics.
Lightspeed
A venture capital firm that led the $215 million funding round for Warp Sciences.
The details
Founded by former executives from OpenAI, Meta, Terremoto Biosciences, and Devoted Health, the company is not developing its own drug pipeline. Instead, it focuses on enabling customers to discover drugs more efficiently by generating real-world data.
Timeline
In 2024, the Biotechnology Innovation Organization surveyed contract use.
The BIOSECURE Act was signed into law in December 2025.
Warp Sciences emerged from stealth in October 2026.
The Tech Race
The emergence of Warp Sciences reflects a broader industry pivot toward domestic research infrastructure in response to the BIOSECURE Act. This move aims to replace the traditional reliance on offshore service providers, which a 2024 survey showed still supported 74% of biotech firms.
For biotech customers, this new service offers a potential workflow improvement by accelerating the lead optimization phase of drug discovery. By keeping these operations in the U.S., the company may provide developers with more direct control over their research data.
The takeaway
The firm provides a model for how AI and robotics can potentially reduce reliance on international preclinical service contracts. Companies looking to optimize their research should monitor how automated lab data can integrate into their existing discovery cycles.
Further reading
For more on the current state of drug discovery tools, visit South San Francisco biotech.
Source note: This article includes information reported by The Robot Report.
Live Poll
Should the U.S. prioritize keeping pharmaceutical and biotech research discovery processes within domestic borders?
